Drug Profile
COVID eVax - Takis
Alternative Names: 2019-nCoV coronavirus vaccine - Takis; Coronavirus vaccine - Takis; COVID-eVaxLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Takis
- Developer Rottapharm Biotech; Takis
- Class COVID-19 vaccines; DNA vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 03 Feb 2021 The Italian Medicines Agency approves clinical trial application for COVID-eVax in COVID-2019 infections (Prevention)
- 03 Feb 2021 Phase-I/II clinical trials in COVID-2019 infections (Prevention, In volunteers) in Italy (IM, Injection) (EudraCT2020-003734-20) (NCT04788459)
- 22 Sep 2020 Pharmacodynamics data from a preclinical study in COVID-2019 infections released by Takis